Bio Break: The Power of Ablation
In this episode of Bio Break, Nick and Joris dive into the rapidly growing field of minimally invasive medical technologies, focusing on a powerful technique that’s reshaping patient outcomes: ablation.
Joris explains that where open surgery was once the norm—think long hospital stays and extensive recovery—today’s patients can often benefit from procedures that require only small incisions and short hospital visits. At the core of many of these advancements is ablation technology.
So, what exactly is ablation? It’s the targeted removal of tissue from the body, usually done by a healthcare professional using minimally invasive tools. There are several types (chemical ablation, electrical ablation, and thermal ablation) each suited to different conditions and tissues. But regardless of the method, the goal is the same: safely and precisely eliminate unwanted or problematic tissue while minimizing disruption to the body.
Nick and Joris explore some of the most compelling use cases. From treating small tumors to managing chronic pain and even correcting cardiac arrhythmias, ablation is proving to be a versatile solution. One standout application is pain management, where ablation can target specific nerves responsible for chronic pain, such as persistent back issues. In cardiology, it’s commonly used to address irregular heart rhythms by disrupting malfunctioning electrical pathways.
And while the procedure offers numerous benefits, shorter recovery times, reduced risk of complications, and improved patient comfort, there are also important considerations. Since the procedure doesn’t involve fully opening the body, visibility is limited. That’s why sophisticated medical imaging is critical to its success. As a result, ablation is typically performed in advanced hospital settings with access to the right tools and expertise.
The Power of Ablation
Related Resources
Nigel Syrotuck breaks down REACH SVHC compliance for teams working with material suppliers and compliance questionnaires.
We examine when computational modelling and simulation, or CM&S, genuinely supports medical device simulation strategy and when it becomes a costly detour.
Many teams still underuse CM&S, often bringing it late in device validation, when key decisions have already been made. That approach leaves much of the value of CM&S untapped.
This article traces the Pennes bioheat equation from its 1948 origins to modern multiscale approaches, explaining how engineers select the right level of modelling complexity across device categories.